BNP Paribas Financial Markets’s iBio IBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10 Hold
5
﹤0.01% 5767
2025
Q4
$10 Hold
5
﹤0.01% 5691
2025
Q3
$4 Hold
5
﹤0.01% 5543
2025
Q2
$4 Buy
5
+3
+150% +$3 ﹤0.01% 5421
2025
Q1
$8 Hold
2
﹤0.01% 5343
2024
Q4
$5 Hold
2
﹤0.01% 5375
2024
Q3
$4 Hold
2
﹤0.01% 4132
2024
Q2
$4 Sell
2
-500
-100% -$1.07K ﹤0.01% 4029
2024
Q1
$2.04K Buy
+502
New +$631 ﹤0.01% 3814
2022
Q3
Sell
-51
Closed -$6.79K 4867
2022
Q2
$6.79K Sell
51
-6
-11% -$902 ﹤0.01% 3793
2022
Q1
$12.1K Sell
57
-115
-67% -$24.1K ﹤0.01% 3777
2021
Q4
$47.1K Buy
172
+50
+41% +$19.1K ﹤0.01% 3752
2021
Q3
$64.9K Buy
122
+61
+100% +$38K ﹤0.01% 3443
2021
Q2
$45.9K Sell
61
-3
-5% -$2.19K ﹤0.01% 3287
2021
Q1
$49.2K Sell
64
-10
-14% -$8.71K ﹤0.01% 3612
2020
Q4
$39K Buy
74
+49
+196% +$39.9K ﹤0.01% 3664
2020
Q3
$25.3K Buy
25
+21
+525% +$30.4K ﹤0.01% 3750
2020
Q2
$4K Buy
+4
New +$2.62K ﹤0.01% 4082
2014
Q3
Hold
0
-$502 4184
2014
Q2
Hold
0
3585
2014
Q1
Hold
0
3027
2013
Q4
Hold
0
3959

Other funds holding IBIO

BNP Paribas Financial Markets's IBIO Position: Q1 2026 in Review

BNP Paribas Financial Markets held its iBio (IBIO) position steady in Q1 2026 at 5 shares worth $10. The position accounts for ﹤0.01% of the portfolio, ranked #5767.

BNP Paribas Financial Markets first reported a position in IBIO in Q2 2020 and has held it in 18 quarters since. The position peaked at $64.9K in Q3 2021. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

  • BNP Paribas Financial Markets held 5 shares of iBio worth $10 as of Q1 2026.
  • BNP Paribas Financial Markets left its iBio share count unchanged in Q1 2026.
  • iBio made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5767 holding.
  • BNP Paribas Financial Markets first reported a position in iBio in Q2 2020 and has held it in 18 quarters since.
  • BNP Paribas Financial Markets's iBio position peaked at $64.9K in Q3 2021.
  • 52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.